A.D.A.

·       Company description/summary:

A.D.A. (Advanced Drug Administration) is an Italian company focused on the development of nanomedicine-based inhalation therapies to treat interstitial lung diseases (ILDs). Our goal is to overcome the limitations of current systemic therapies by developing locally active formulations with improved efficacy and lower side effects.

·       Summary products/description:

Interstitial lung diseases are characterized by immune-mediated inflammation and fibrotic processes, for which developing the right therapeutic approach is very challenging. Current therapies are designed to target only individual symptoms and single disease manifestations. To solve this problem, A.D.A. is developing nanomedicine-based inhalation therapies that can target multiple signaling pathways at the same time. 

Our patent-pending candidates are self-assembling immunosuppressive nanoparticles (lead candidate ADA2) that can also act as a platform (new concept of "Drug AND Delivery") to deliver anti-fibrotic drugs into the lungs, such as our second inhaled formulation (lead candidate ADA1) that treats the fibrotic manifestation of interstitial lung diseases (ILDs). Our combination therapy is the only treatment worldwide to simultaneously target the hyperactivation of the immune system and the fibrotic process.